Asaleo Care Limited (ASX: AHY) – Share price soars high despite reporting of losses

Asaleo Care presented 2018 half year results for the 6 months ended 30 June 2018 on Tuesday 21 August 2018. Personal care company reported underlying Net Loss After Tax (NLAT) of $101.5 million for 1H18 compared to $27.7 million profit in the previous corresponding year. The statutory result includes non-cash one off impairment cost of $148.5 million.

Underlying 1H18 earnings before interest tax, depreciation and amortization declined 24% to $46.3m which includes Tissue EBITDA of $20.0m, down 38.8%, and Personal Care EBITDA of $26.3m, down 6.7% on 1H17. Revenue decreased by 9% to $267.2 million in first half of 2018 due to lower retail sales volumes and higher costs.

The group has achieved price increase during the reporting period but there has been no price increase from their rivalries. As a result, sales volumes lowered down in price negotiation with customers. The company reported weaker returns with 3.3 cents earning per share and 12% return on invested capital for 1H18.The board has declared no interim dividend for the half year 2018.

In FY18 guidance, company forecasts $80 million to $85 million underlying EBITDA.

Despite receiving announcement on lower sales volume and resultant losses incurred during the first half of 2018, investors continued to inject money in personal care provider, AHY as share price moved up by 11.9% to $0.795 on Tuesday (as the result was earlier expected to be much worse than what has been reported).

Dividend Stocks To Buy

The Income available from dividends remains attractive for many investors.

We take a look at the best yields on the market and assess what they say about a company’s prospect.

One Thing is certain, though, Australia interest rates are still low, making income difficult to come by and keeping the focus for many investors on high yielding stocks. Kalkine’s team of analysts bought you handpicked report for “Top 25 Dividend Stocks For 2018.”

ASX-relevant Special Reports are published year-round to provide a detailed analysis into an investing opportunity or a potential risk to your portfolio.

Click here to get your free report.


The advice given by Kalkine Pty Ltd and provided on this website is general information only and it does not take into account your investment objectives, financial situation or needs. You should therefore consider whether the advice is appropriate to your investment objectives, financial situation and needs before acting upon it. You should seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice. Not all investments are appropriate for all people. and associated websites are published by Kalkine Pty Ltd ABN 34 154 808 312 (Australian Financial Services License Number 425376). website), employees and/or associates of Kalkine Pty Ltd do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations.

Join Our Discussion

Start discussion with value Investors for ASX Stock Market Investment and Opinion.

6 Cannabis Stocks under Investor’s Limelight…

Cannabis companies that sell both medicinal weed and recreational pot. Marijuana stocks to look at. Marijuana mergers and acquisitions. Dispensary data analytics. Upcoming marijuana IPO’s Those phrases have become increasingly common as marijuana legalization spreads.

Global spending on legal cannabis is expected to grow 230% to $32 billion in 2020 as compared to $9.5 in 2017, according to Arcview Market Research and BDS Analytics. As of June 29, 2018 the United States Marijuana Index, despite a lot of uncertainty around regulations, has over the past 1 year gained 71.49%, as compared to about 12% gain seen by the S&P 500.

Click here for your FREE Report